Product imageResearch use only

CAT. NO. DC82003

A12-Iso5-2DC18

Research highlights

A12 is the A12-Iso5-2DC18 lipidoid prepared from 3-(dimethylamino)propylamine, ethyl isocyanoacetate and 9,26-pentatriacontadien-18-one.A12 and A2 showed similar local/draining-lymph-node expression and APC transfection in the cited mouse experiments.A12 mOVA LNPs produced weaker antigen-specific CTL/IFN-gamma responses and little anti-tumor efficacy than A2 mOVA LNPs in the B16F10-OVA model.The patent's optimized study formulation family used A2:DOPE:cholesterol:C14-PEG = 35:16:37.5:2.5 mol% with a lipid:mRNA weight ratio of 10:1; the patent does not print a separately optimized A12 ratio.

Pack size & price

USD

Total$750

We match the best price and quality on market.

Ships from ShanghaiIce-pack transportPure lipid recommended

Product overview

Description & Application

A12-Iso5-2DC18 is a novel amine containing lipid can be used for mRNA delivery, activate the stimulator of interferon genes (STING) pathway, and exhibit anti-tumor immunity.

CAS No.	2412492-06-7
Chemical Name	A12-Iso5-2DC18
Synonyms	1H -Imidazole-2-carboxylic acid, 1-[3-(dimethylamino)propyl]-5,5-di- (8Z )-8-heptadecen-1-yl-2,5-dihydro-, ethyl ester (ACI);A12Iso52DC18， A12 Iso5 2DC18
SMILES	C(CCCCCC/C=C\CCCCCCCC)C1(CCCCCCC/C=C\CCCCCCCC)N(CCCN(C)C)C(C(OCC)=O)N=C1
Formula	C45H85N3O2
M.Wt	700.18
Purity	>95% by ELSD-HPLC
Storage	Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping condition	Ships from Shanghai. Pure lipid is stable during ice-pack transport.
Publication	Miao L, Li L, Anderson DG, Huang Y. Ionizable lipidoids and their uses. WO2020047399A1, 2020.

Literature-reported formulation composition

Component	mol%	Role
A12-Iso5-2DC18	35	Ionizable lipid
DOPE	16	Helper phospholipid
Cholesterol	37.5	Sterol
C14-PEG	2.5	PEG lipid
Reported total	91	Source values retained

Formulation calculator unavailable. The A2 model ratio is retained as reported for context only. A12-specific helper-lipid identity, PEG molecular weight and exact optimized ratio are not sufficiently resolved for a fixed calculator. Obtain and verify the complete composition and component molecular weights before planning component quantities.

N/P ratioNot reported in the cited article

Total lipid:cargo weight ratio10:1 for the exemplary optimized A2 model formulation; not separately reported for A12.

CargoFirefly luciferase mRNA, Cre-recombinase mRNA and ovalbumin mRNA (mOVA).

Administration routeSubcutaneous and intramuscular injection for screening/vaccine studies; Cre mRNA was delivered to Ai14 reporter mice.

DosemLuc 0.1 or 0.5 mg/kg in the A2/A12 comparison; mOVA 15 microgram per mouse in CTL assays. The patent also reports the broader screen at 0.5 mg/kg mLuc per mouse.

Animal modelFemale B6 mice; Ai14 reporter mice; B16F10-OVA mouse melanoma model; BMDCs, BMDMs and HeLa cells.

Formulation processThe patent describes individual LNP preparation from an ionizable lipidoid, helper lipid, cholesterol and C14-PEG; the accessible patent text does not provide a complete A12-specific flow-rate recipe.

Literature-reported performance for the cited formulation

Literature-reportedmRNA deliveryA12 and A2 induced similar levels of protein expression in local tissue and draining lymph nodes and transfected macrophage/monocyte and dendritic-cell populations.mLuc or Cre mRNA LNPs in mice · A2 LNPsWO2020047399A1 [00266], Figures 3B-3G and 12.

Literature-reportedAntigen-specific immunityA12 mOVA LNPs produced lower CTL and IFN-gamma responses than A2 mOVA LNPs in the cited comparison.mOVA vaccination · A2 mOVA LNPsWO2020047399A1 [00267], Figures 3H and 13.

Literature-reportedAnti-tumor efficacyA12 mOVA LNPs showed almost no anti-tumor efficacy in the B16F10-OVA model under the reported conditions.Two-dose mOVA vaccination, once every five days · A2 mOVA LNPsWO2020047399A1 [00267]-[00268], Figure 3I.

Literature-reportedRelative deliveryBoth A2 and A12 were identified as high-performing 2DC18/ethyl-isocyanoacetate lipidoids and were approximately two-fold higher than Dlin-KC3-DMA in the cited comparison.In-vitro and in-vivo screening · Dlin-KC3-DMAWO2020047399A1 [00263].

Additional reported findings

Structure-function context

The patent links reduced tail saturation, the 2DC18 ketone and ethyl isocyanoacetate substructure with improved delivery across the broader lipidoid library; these are library-level observations and not A12-only causal tests.

· WO2020047399A1 [00262]-[00263].

Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.

Cited literature for this formulation and performance datasetMiao L, Li L, Anderson DG, Huang Y. Ionizable lipidoids and their uses. WO2020047399A1, 2020. DOI: https://patents.google.com/patent/WO2020047399A1/en
All quantitative and biological claims apply to the patent's reported A12/A2 LNP study conditions, not to the neat lipid alone.

Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

No A12-specific N/P or lipid:RNA ratio was reported; the patent's A2 model 10:1 lipid:mRNA ratio is labeled as A2-only context.

Mass = concentration × volume × molecular weight

MassConcentrationVolumeMolecular weightg/mol

Enter any three values to calculate the fourth.

C₁V₁ = C₂V₂

C₁mMV₁mLC₂mMV₂mL

Enter any three values to calculate the fourth.

Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass	1 mM	5 mM	10 mM
10 mg	14.2820 mL	2.8564 mL	1.4282 mL
25 mg	35.7051 mL	7.1410 mL	3.5705 mL
50 mg	71.4102 mL	14.2820 mL	7.1410 mL
100 mg	142.8204 mL	28.5641 mL	14.2820 mL
250 mg	357.0510 mL	71.4102 mL	35.7051 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?

We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.

Pure lipid or solution — which should I choose?

Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.

How should I measure a small amount of oily or viscous lipid?

Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.

Can you support formulation optimization and scale-up?

Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.

A12-Iso5-2DC18

Pack size & price

Description & Application

Recommended Products

ALC-0315

SM-102

C12-200

Iso-A11B5C1

C18 NC-TNP

Lipid A4B4-S3

Lipid TOT-5

YK-TLR-001

A2T2C9 (CP-LC-1465)

DMA4-H228